Investing.com - Ascendis Pharma AS reported on Thursday first quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Ascendis Pharma AS announced earnings per share of €1.17 on revenue of €0.7M. Analysts polled by Investing.com anticipated EPS of €-1.83 on revenue of €1.33M.
Ascendis Pharma AS shares are down 18.34% from the beginning of the year and are trading at €136.19 , down-from-52-week-high.They are under-performing the Nasdaq which is up 6.58% from the start of the year.
Ascendis Pharma AS follows other major Healthcare sector earnings this month
Ascendis Pharma AS's report follows an earnings beat by Pfizer on Tuesday, May 4, 2021, who reported EPS of €0.93 on revenue of €14.58B, compared to forecasts EPS of €0.7759 on revenue of €13.65B.
AbbVie had beat expectations on Friday, April 30, 2021 with first quarter EPS of €2.95 on revenue of €13.01B, compared to forecast for EPS of €2.81 on revenue of €12.77B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar